검색어: bethesda (영어 - 스웨덴어)

bethesda
bethesda

fledermausquartier ‘haus bethesda’
fledermausquartier ”haus bethesda”

the bethesda group of bacteria
citrobacter freundii

inhibitory activity, as measured by the modified bethesda assay, was not detected in this patient.
inhibitorisk aktivitet, enligt mätning med det modifierade bethesda-testet, detekterades inte hos denna patient.

inhibitor titres of up to 29 bethesda units were recorded at baseline yet subjects responded positively to obizur.
hämmande titrer på upp till 29 bethesda-enheter har registrerats vid baslinjen, men ändå har patienterna svarat positivt på obizur.

it is recommended that treatment should be based on clinical judgement and not based on detection of inhibitory antibodies by the bethesda assay.
det rekommenderas att behandlingen baseras på klinisk bedömning och inte på detektion av hämmande antikroppar genom bethesda-analys.

in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu)
hos patienter med medfödd hemofili med antikroppar mot koagulationsfaktorer viii eller ix > 5 bethesda- enheter

now there is at jerusalem by the sheep market a pool, which is called in the hebrew tongue bethesda, having five porches.
vid fårporten i jerusalem ligger en damm, på hebreiska kallad betesda, och invid den finnas fem pelargångar.

these inhibitors are invariably igg immunoglobulins directed against the factor viii procoagulant activity, which are quantified in modified bethesda units (bu) per ml of plasma.
dessa inhibitorer är undantagslöst igg immunglobuliner som riktas mot den prokoagulerande aktiviteten hos faktor viii, och kvantifieras i modifierade bethesda- enheter (bu) per ml plasma.

these inhibitors are usually iggs directed against the factor viii procoagulant activity, which are quantified in bethesda units (bu) per ml of plasma using the modified bethesda assay.
dessa inhibitorer är vanligtvis igg riktade mot den prokoagulerande effekten hos faktor viii, vilken kvantifieras i bethesda- enheter (be) per ml plasma med det modifierade bethesda- testet.

since during clinical studies one ptp treated with benefix developed a clinically relevant low responding inhibitor and experience on antigenicity with recombinant factor ix is still limited, patients treated with benefix should be carefully monitored for the development of factor ix inhibitors that should be titrated in bethesda units using appropriate biological testing.
detta bör göras genom titrering i bethesda- enheter med användning av lämpligt biologisk test.

if the inhibitor is present at levels less than 10 bethesda units (bu) per ml, administration of additional recombinant coagulation factor viii may neutralise the inhibitor and permit continued clinically effective therapy with helixate nexgen.
om inhibitorkoncentrationen är lägre än 10 bethesda-enheter (bu) per ml kan tillförsel av ytterligare rekombinant koagulationsfaktor viii neutralisera inhibitorn och medge fortsatt kliniskt effektiv behandling med helixate nexgen.

during clinical trials with advate in 145 paediatric and adult patients 2 diagnosed with severe to moderately severe haemophilia a (fviii ≤ 2%), with previous exposure to factor viii concentrates ≥ 150 days, one patient developed a low-titre inhibitor (2.4 bu in the modified bethesda assay) after 26 exposure days to advate.
under kliniska prövningar med advate på 145 barnpatienter och vuxna patienter 2 med diagnosen svår till medelsvår hemofili a (fviii ≤ 2%) och som tidigare utsatts för faktor viii- koncentrat ≥ 150 dagar, utvecklade en patient en lågtiter- inhibitor (2, 4 be i det modifierade bethesdatestet) efter att ha utsatts för advate i 26 dagar.